For patients with SVR and F3 fibrosis who lack additional risk factors, continued annual AFP, US surveillance, and TE are recommended, but these can be discontinued if TE confirms regression to F2 or less, where the risk of HCC becomes minimal (Figure 1). Here, AFP is linked to hepatocellular carcinoma.